ClinicalTrials.gg
CompletedNCT02847637HAVEN 3Updated Nov 16, 2022Results posted

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

A Phase 3 interventional study of Emicizumab and Factor VIII (FVIII) in Hemophilia A, sponsored by Hoffmann-La Roche. Completed at 39 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-11-16.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.

Enrollment
2nd of 22
152 · median 27
Started
2016
with 1 other
Phase 3
11 of 22
none open now
Registered
3rd of 22
by date
Lead sponsor
10 of 22
Hoffmann-La Roche

Among the 22 studies testing emicizumab in Hemophilia A, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 11 in phase 3, and was the 3rd registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About emicizumab

emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing emicizumab in Hemophilia A, or all of them as a file.
02

Study summary

This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.

03

Conditions studied

  • Hemophilia A

Browse trials for

Keywords

  • Hemophilia A
  • Emicizumab
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight >/= 40 kilogram (kg) at the time of screening
  • Diagnosis of severe congenital hemophilia A
  • Documentation of the details of prophylactic or episodic FVIII treatment and of number of bleeding episodes for at least the last 24 weeks
  • Adequate hematologic function
  • Adequate hepatic function
  • Adequate renal function
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of less than (\<) 1 percent (%) per year during the treatment period and for at least 5 elimination half-lives (24 weeks) after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Inherited or acquired bleeding disorder other than hemophilia A
  • Previous or current treatment for thromboembolic disease or signs of thromboembolic disease
  • Conditions that may increase risk of bleeding or thrombosis
  • History of associated with monoclonal antibody therapies or components of the emicizumab injection
  • Known (HIV) infection with cluster of differentiation (CD) 4 count \<200 cells per microliter (cells/mcL) within 24 weeks prior to screening. Participants with HIV infection who has CD4 greater than (>) 200 and meet all other criteria are eligible
  • Use of systemic immunomodulators at enrollment or planned use during the study, with the exception of anti-retroviral therapy
  • Participants who are at high risk for thrombotic microangiopathy (TMA) (for example, have a previous medical or family history of TMA), in the investigator's judgment
  • Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study
  • Planned surgery (excluding minor procedures) during the study
  • Receipt of emicizumab in a prior study; an investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration; a non-hemophilia-related investigational drug concurrently, within last 30 days or 5 half-lives, whichever is shorter
  • Pregnant or lactating, or intending to become pregnant during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Active comparator
    Arm C (Control): No Prophylaxis, Then Emicizumab

    Participants who had received episodic treatment with FVIII prior to study entry were randomized to continue episodic FVIII treatment when they started the trial. After completing 24 weeks of no prophylaxis (i.e., episodic FVIII treatment) on study, then they were given the opportunity to switch to emicizumab prophylaxis of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 3 mg/kg emicizumab SC once every 2 weeks (Q2W). Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.

    Drug: Emicizumab · Drug: Factor VIII (FVIII)

  • Experimental
    Arm A: Emicizumab 1.5 mg/kg QW

    Participants who had received episodic treatment with FVIII prior to study entry were randomized to receive emicizumab prophylaxis at a dose of 3 milligrams per kilogram (mg/kg) subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 1.5 mg/kg emicizumab SC QW. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.

    Drug: Emicizumab · Drug: Factor VIII (FVIII)

  • Experimental
    Arm B: Emicizumab 3 mg/kg Q2W

    Participants who had received episodic treatment with FVIII prior to study entry were randomized to receive emicizumab prophylaxis at a dose of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 3 mg/kg emicizumab SC once every 2 weeks (Q2W). Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.

    Drug: Emicizumab · Drug: Factor VIII (FVIII)

  • Experimental
    Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)

    Participants who had received FVIII prophylaxis prior to study entry were enrolled to receive emicizumab prophylaxis at a dose of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 1.5 mg/kg emicizumab SC QW. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.

    Drug: Emicizumab · Drug: Factor VIII (FVIII)

Interventions

  • Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.

    Also known as: Hemlibra, RO5534262, ACE910

  • FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.

06

What researchers measure

Primary outcomes

  1. Annualized Bleeding Rate (ABR) for Treated Bleeds

    The number of treated bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a negative binomial (NB) regression model, which accounts for different follow-up times, with the number of bleeds as a function of randomization and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.

    Time frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)

Secondary outcomes

  1. Annualized Bleeding Rate (ABR) for All Bleeds

    The number of all bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.

    Time frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)

  2. Annualized Bleeding Rate (ABR) for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A "joint bleed" is defined as a bleed reported as "joint" and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint; and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. It is considered a "treated joint bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.

    Time frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)

  3. Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A bleed is classified as "spontaneous" if there is no other known contributing factor such as trauma or procedure/surgery. A "treated spontaneous bleed" is a spontaneous bleed that is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.

    Time frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)

  4. Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds

    The number of treated target joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A "target joint bleed" is defined as a bleed reported as a joint bleed into a target joint, defined as at least 3 bleeds into the same joint during the last 24 weeks prior to study entry. It is considered a "treated target joint bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.

    Time frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)

  5. Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With Factor VIII (FVIII) Prophylaxis (NISP)

    This is an intra-participant comparison of the annualized bleeding rate (ABR) for treated bleeds on study versus pre-study in the NIS population previously treated with FVIII prophylaxis in NIS BH29768. The number of treated bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.

    Time frame: Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for Dnisp-FVIII Prophylaxis: 30.07 [5.0-45.1] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for Dnisp-Emicizumab Prophylaxis: 33.71 [20.1-48.6] weeks)

  6. Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With FVIII Prophylaxis (NISP)

    This is an intra-participant comparison of the annualized bleeding rate (ABR) for all bleeds on study versus pre-study in the NIS population previously treated with FVIII prophylaxis in NIS BH29768. The number of all bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the participant's number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.

    Time frame: Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for Dnisp-FVIII Prophylaxis: 30.07 [5.0-45.1] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for Dnisp-Emicizumab Prophylaxis: 33.71 [20.1-48.6] weeks)

  7. Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE)

    This is an intra-participant comparison of the annualized bleeding rate (ABR) for treated bleeds on study versus pre-study in the NIS population previously treated with episodic FVIII in NIS BH29768. The number of treated bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.

    Time frame: Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for A+Bnise-FVIII Episodic: 25.71 [15.4-40.9] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for A+Bnise-Emicizumab: 34.71 [24.1-50.6] weeks)

  8. Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE)

    This is an intra-participant comparison of the annualized bleeding rate (ABR) for all bleeds on study versus pre-study in the NIS population previously treated with episodic FVIII in NIS BH29768. The number of all bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the participant's number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.

    Time frame: Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for A+Bnise-FVIII Episodic: 25.71 [15.4-40.9] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for A+Bnise-Emicizumab: 34.71 [24.1-50.6] weeks)

  9. Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Physical Health Subscore for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 25

    The Haem-A-QoL questionnaire has been developed and used in hemophilia A participants, assessing very specific aspects of dealing with hemophilia. The questionnaire consists of items pertaining to 10 domains: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain ranges from 0 to 100 with lower scores reflective of better quality of life. Physical Health domain score is reported (range 0 to 100, with lower scores reflective of better physical health). The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.

    Time frame: Baseline, Week 25

  10. Haem-A-QoL Questionnaire Total Score for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 25

    The Haem-A-QoL questionnaire has been developed and used in hemophilia A participants, assessing very specific aspects of dealing with hemophilia. The questionnaire consists of items pertaining to 10 domains: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain ranges from 0 to 100 with lower scores reflective of better quality of life. Haem-A-QoL Total Score is the average of all domain scores and it ranges from 0 to 100, with lower scores reflective of better quality of life. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.

    Time frame: Baseline, Week 25

  11. European Quality of Life 5-Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score in the Randomized Population at Week 25

    EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L VAS. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.

    Time frame: Baseline, Week 25

  12. EQ-5D-5L Questionnaire Index Utility Score in the Randomized Population at Week 25

    EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L VAS. The EQ-5D-5L health state profile is designed to record the participant's current health state in 5 domains: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. Responses from the five domains are used to calculate a single index utility score on a scale of 0 to 1, with higher scores reflective of better quality of life. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.

    Time frame: Baseline, Week 25

  13. Hemophilia-Specific Quality of Life - Short Form (Haemo-QoL-SF) Questionnaire Score in Adolescent Participants (12 to 17 Years of Age) in the Randomized Population at Week 25

    The Haemo-QoL-SF contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia and treatment). Items are rated with five respective response options: never, seldom, sometimes, often, and always. Haemo-QoL-SF total score range from 0 to 100, where lower scores reflect better health-related quality of life.

    Time frame: Week 25

  14. Percentage of Participants With at Least One Adverse Event During the First 24 Weeks of the Study, Primary Analysis

    The percentage of participants experiencing at least one adverse event, including all non-serious and serious adverse events, is reported here. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

    Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)

  15. Percentage of Participants With at Least One Grade ≥3 Adverse Event During the First 24 Weeks of the Study, Primary Analysis

    The World Health Organization (WHO) toxicity grading scale will be used for assessing adverse event severity. For adverse events that are not specifically listed in the WHO toxicity grading scale, a grade 3 adverse event is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a grade 4 adverse event is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

    Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)

  16. Percentage of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment During the First 24 Weeks of the Study, Primary Analysis

    At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

    Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)

  17. Percentage of Participants With at Least One Adverse Event of Changes From Baseline in Vital Signs During the First 24 Weeks of the Study, Primary Analysis

    The percentage of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

    Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)

  18. Percentage of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings During the First 24 Weeks of the Study, Primary Analysis

    Post-baseline physical examination abnormalities that were not present at baseline or worsened were reported as adverse events. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

    Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)

  19. Percentage of Participants With at Least One Adverse Event of Abnormal Laboratory Values During the First 24 Weeks of the Study, Primary Analysis

    The percentage of participants with adverse events of abnormal laboratory values is reported here. An abnormal laboratory value is defined as a laboratory test result outside of the normal range for hematology or serum chemistries. It is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

    Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)

  20. Percentage of Participants With at Least One Local Injection-Site Reaction During the First 24 Weeks of the Study, Primary Analysis

    Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an "injection-site reaction" on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a "local injection-site reaction." At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

    Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)

  21. Percentage of Participants With at Least One Thromboembolic Event During the First 24 Weeks of the Study, Primary Analysis

    At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.

    Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)

  22. Percentage of Participants With at Least One Thrombotic Microangiopathy During the First 24 Weeks of the Study, Primary Analysis

    At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

    Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)

  23. Percentage of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction During the First 24 Weeks of the Study, Primary Analysis

    At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

    Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)

  24. Safety Summary of the Percentage of Emicizumab-Treated Participants With at Least One Adverse Event During the Study

    Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. For participants whose emicizumab dose was up-titrated and those who opted for a change in dosing regimen (after implementation of protocol v4), only AEs that occurred before either one of those events are included. Hypersens.= hypersensitivity; Mod. = modification

    Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)

  25. Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants

    The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

    Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)

  26. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants

    The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

    Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)

  27. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants

    The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

    Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)

  28. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

    The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks

  29. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

    The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks

  30. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

    The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks

  31. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

    The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks

  32. Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

    The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks

  33. Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

    The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

    Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks

  34. Percentage of Participants With Anti-Emicizumab Antibodies at Any Time Post-Baseline During the Study

    A validated enzyme-linked immunosorbent assay (ELISA) method was used to analyze the levels of anti-drug antibodies (ADAs) against emicizumab in plasma. A sample was considered positive for anti-emicizumab antibodies if the test result reached or exceeded a pre-determined threshold. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample.

    Time frame: From Baseline to discontinuation from study (median [min-max] observation period for all emicizumab participants: 262.3 [14.4-288.3] weeks)

  35. Percentage of Participants With De Novo Development of Factor VIII (FVIII) Inhibitors

    Levels of anti-FVIII antibodies (inhibitors) were analyzed using a validated FVIII activity assay. A participant was considered to have developed de novo FVIII inhibitors if the inhibitor levels detected in a post-baseline sample reached or exceeded a pre-determined threshold.

    Time frame: From Baseline to discontinuation from study (median [min-max] observation period for all emicizumab participants: 262.3 [14.4-288.3] weeks)

  36. Trough Plasma Concentration (Ctrough) of Emicizumab

    Trough plasma concentrations of emicizumab were analyzed using a validated Enzyme Linked Immunosorbent Assay (ELISA). The lower limit of quantification (LLOQ) was 100 nanograms per milliliter (ng/mL). Because participants in Arm C (Control) switched from no prophylaxis to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm C (Emi) are expressed relative to first emicizumab dose.

    Time frame: Predose at Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181, 193, 205, 217, 229, 241, 253, 265, and 277

07

Results

Posted Nov 14, 2018

Participant flow

Participant flow — Overall Study
MilestoneArm C (Control): No Prophylaxis, Then EmicizumabArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Started18363563
Completed first 24 weeks of treatment16353463
Emicizumab dose was up-titrated0117
Opted to change emicizumab dosing regimen1311
Completed17343463
Not completed1210
Withdrew: Withdrawal by subject0110
Withdrew: Lost to follow-up1100

Outcome measures

PrimaryAnnualized Bleeding Rate (ABR) for Treated Bleeds

The number of treated bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a negative binomial (NB) regression model, which accounts for different follow-up times, with the number of bleeds as a function of randomization and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.

Time frame:
From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Reported as:
Number · treated bleed rate per year
Annualized Bleeding Rate (ABR) for Treated Bleeds
treated bleed rate per yearArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Annualized Bleeding Rate (ABR) for Treated Bleeds38.2 (22.86 to 63.76)1.5 (0.89 to 2.47)1.3 (0.75 to 2.25)1.6 (1.07 to 2.44)
Statistical analysis
  • Arm C (Control): No Prophylaxis vs Arm A: Emicizumab 1.5 mg/kg QW · Stratified Wald test · p = <0.0001 (Statistical significance is controlled at the 2-sided, 0.05 alpha level. The p-value was obtained via a global model with a 3-level categorical effect for treatment (emicizumab 1.5 mg/kg/week, emicizumab 3 mg/kg/2 weeks, or no prophylaxis).) · Abr ratio: 0.04 · 95% CI 0.020 to 0.075Arm A is the numerator and Arm C is the denominator for this ABR Ratio.
  • Arm C (Control): No Prophylaxis vs Arm B: Emicizumab 3 mg/kg Q2W · Stratified Wald test · p = <0.0001 (Statistical significance is controlled at the 2-sided, 0.05 alpha level. The p-value was obtained via a global model with a 3-level categorical effect for treatment (emicizumab 1.5 mg/kg/week, emicizumab 3 mg/kg/2 weeks, or no prophylaxis).) · Abr ratio: 0.03 · 95% CI 0.017 to 0.066Arm B is the numerator and Arm C is the denominator for this ABR Ratio.
SecondaryAnnualized Bleeding Rate (ABR) for All Bleeds

The number of all bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.

Time frame:
From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Reported as:
Number · all bleed rate per year
Annualized Bleeding Rate (ABR) for All Bleeds
all bleed rate per yearArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Annualized Bleeding Rate (ABR) for All Bleeds47.6 (28.45 to 79.59)2.5 (1.63 to 3.90)2.6 (1.63 to 4.29)3.3 (2.22 to 4.83)
Statistical analysis
  • Arm C (Control): No Prophylaxis vs Arm A: Emicizumab 1.5 mg/kg QW · Stratified Wald test · p = <0.0001 (Statistical significance is controlled at the 2-sided, 0.05 alpha level. The p-value was obtained via a global model with a 3-level categorical effect for treatment (emicizumab 1.5 mg/kg/week, emicizumab 3 mg/kg/2 weeks, or no prophylaxis).) · Abr ratio: 0.05 · 95% CI 0.028 to 0.099Arm A is the numerator and Arm C is the denominator for this ABR Ratio.
  • Arm C (Control): No Prophylaxis vs Arm B: Emicizumab 3 mg/kg Q2W · Stratified Wald test · p = <0.0001 (Statistical significance is controlled at the 2-sided, 0.05 alpha level. The p-value was obtained via a global model with a 3-level categorical effect for treatment (emicizumab 1.5 mg/kg/week, emicizumab 3 mg/kg/2 weeks, or no prophylaxis).) · Abr ratio: 0.06 · 95% CI 0.030 to 0.103Arm B is the numerator and Arm C is the denominator for this ABR Ratio.
SecondaryAnnualized Bleeding Rate (ABR) for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A "joint bleed" is defined as a bleed reported as "joint" and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint; and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. It is considered a "treated joint bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.

Time frame:
From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Reported as:
Number · treated joint bleed rate per year
Annualized Bleeding Rate (ABR) for Treated Joint Bleeds
treated joint bleed rate per yearArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Annualized Bleeding Rate (ABR) for Treated Joint Bleeds26.5 (14.67 to 47.79)1.1 (0.59 to 1.89)0.9 (0.44 to 1.67)1.2 (0.70 to 2.01)
Statistical analysis
  • Arm C (Control): No Prophylaxis vs Arm A: Emicizumab 1.5 mg/kg QW · Stratified Wald test · p = <0.0001 (Statistical significance is controlled at the 2-sided, 0.05 alpha level. The p-value is obtained via a global model with a 3-level categorical effect for treatment (emicizumab 1.5 mg/kg/week, emicizumab 3 mg/kg/2 weeks, or no prophylaxis).) · Abr ratio: 0.04 · 95% CI 0.019 to 0.085Arm A is the numerator and Arm C is the denominator for this ABR Ratio.
  • Arm C (Control): No Prophylaxis vs Arm B: Emicizumab 3 mg/kg Q2W · Stratified Wald test · p = <0.0001 (Statistical significance is controlled at the 2-sided, 0.05 alpha level. The p-value is obtained via a global model with a 3-level categorical effect for treatment (emicizumab 1.5 mg/kg/week, emicizumab 3 mg/kg/2 weeks, or no prophylaxis).) · Abr ratio: 0.03 · 95% CI 0.015 to 0.070Arm B is the numerator and Arm C is the denominator for this ABR Ratio.
SecondaryAnnualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A bleed is classified as "spontaneous" if there is no other known contributing factor such as trauma or procedure/surgery. A "treated spontaneous bleed" is a spontaneous bleed that is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.

Time frame:
From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Reported as:
Number · treated spontaneous bleed rate per year
Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds
treated spontaneous bleed rate per yearArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds15.6 (7.60 to 31.91)1.0 (0.48 to 1.91)0.3 (0.11 to 0.75)0.5 (0.23 to 0.94)
Statistical analysis
  • Arm C (Control): No Prophylaxis vs Arm A: Emicizumab 1.5 mg/kg QW · Stratified Wald test · p = <0.0001 (Statistical significance is controlled at the 2-sided, 0.05 alpha level. The p-value is obtained via a global model with a 3-level categorical effect for treatment (emicizumab 1.5 mg/kg/week, emicizumab 3 mg/kg/2 weeks, or no prophylaxis).) · Abr ratio: 0.06 · 95% CI 0.025 to 0.151Arm A is the numerator and Arm C is the denominator for this ABR Ratio.
  • Arm C (Control): No Prophylaxis vs Arm B: Emicizumab 3 mg/kg Q2W · Stratified Wald test · p = <0.0001 (Statistical significance is controlled at the 2-sided, 0.05 alpha level. The p-value is obtained via a global model with a 3-level categorical effect for treatment (emicizumab 1.5 mg/kg/week, emicizumab 3 mg/kg/2 weeks, or no prophylaxis).) · Abr ratio: 0.02 · 95% CI 0.006 to 0.056Arm B is the numerator and Arm C is the denominator for this ABR Ratio.
SecondaryAnnualized Bleeding Rate (ABR) for Treated Target Joint Bleeds

The number of treated target joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A "target joint bleed" is defined as a bleed reported as a joint bleed into a target joint, defined as at least 3 bleeds into the same joint during the last 24 weeks prior to study entry. It is considered a "treated target joint bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.

Time frame:
From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Reported as:
Number · treated target joint bleed rate per year
Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds
treated target joint bleed rate per yearArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds13.0 (5.22 to 32.33)0.6 (0.28 to 1.42)0.7 (0.27 to 1.64)0.6 (0.26 to 1.53)
Statistical analysis
  • Arm C (Control): No Prophylaxis vs Arm A: Emicizumab 1.5 mg/kg QW · Stratified Wald test · p = <0.0001 (Not controlled for type I error) · Abr ratio: 0.05 · 95% CI 0.016 to 0.143Arm A is the numerator and Arm C is the denominator for this ABR Ratio.
  • Arm C (Control): No Prophylaxis vs Arm B: Emicizumab 3 mg/kg Q2W · Stratified Wald test · p = <0.0001 (Not controlled for type I error) · Abr ratio: 0.05 · 95% CI 0.018 to 0.147Arm B is the numerator and Arm C is the denominator for this ABR Ratio.
SecondaryIntra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With Factor VIII (FVIII) Prophylaxis (NISP)

This is an intra-participant comparison of the annualized bleeding rate (ABR) for treated bleeds on study versus pre-study in the NIS population previously treated with FVIII prophylaxis in NIS BH29768. The number of treated bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.

Time frame:
Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for Dnisp-FVIII Prophylaxis: 30.07 [5.0-45.1] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for Dnisp-Emicizumab Prophylaxis: 33.71 [20.1-48.6] weeks)
Reported as:
Number · treated bleed rate per year
Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With Factor VIII (FVIII) Prophylaxis (NISP)
treated bleed rate per yearDnisp: Pre-Study FVIII Prophylaxis in NIS BH29768Dnisp: Emicizumab Prophylaxis (Pre-Study FVIII Prophylaxis)
Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With Factor VIII (FVIII) Prophylaxis (NISP)4.8 (3.22 to 7.09)1.5 (0.98 to 2.33)
Statistical analysis
  • Dnisp: Pre-Study FVIII Prophylaxis in NIS BH29768 vs Dnisp: Emicizumab Prophylaxis (Pre-Study FVIII Prophylaxis) · Non-stratified Wald test · p = <0.0001 (Statistical significance is controlled at the 2-sided, 0.05 alpha level.) · Abr ratio: 0.32 · 95% CI 0.195 to 0.514Dnisp: Emicizumab Prophylaxis is the numerator and Dnisp: Pre-Study FVIII Prophylaxis is the denominator for this ABR ratio.
SecondaryIntra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With FVIII Prophylaxis (NISP)

This is an intra-participant comparison of the annualized bleeding rate (ABR) for all bleeds on study versus pre-study in the NIS population previously treated with FVIII prophylaxis in NIS BH29768. The number of all bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the participant's number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.

Time frame:
Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for Dnisp-FVIII Prophylaxis: 30.07 [5.0-45.1] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for Dnisp-Emicizumab Prophylaxis: 33.71 [20.1-48.6] weeks)
Reported as:
Number · all bleed rate per year
Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With FVIII Prophylaxis (NISP)
all bleed rate per yearDnisp: Pre-Study FVIII Prophylaxis in NIS BH29768Dnisp: Emicizumab Prophylaxis (Pre-Study FVIII Prophylaxis)
Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With FVIII Prophylaxis (NISP)8.9 (5.72 to 13.87)3.3 (2.17 to 5.06)
Statistical analysis
  • Dnisp: Pre-Study FVIII Prophylaxis in NIS BH29768 vs Dnisp: Emicizumab Prophylaxis (Pre-Study FVIII Prophylaxis) · Non-stratified Wald test · p = 0.0002 (Statistical significance is controlled at the 2-sided, 0.05 alpha level.) · Abr ratio: 0.37 · 95% CI 0.220 to 0.626Dnisp: Emicizumab Prophylaxis is the numerator and Dnisp: Pre-Study FVIII Prophylaxis is the denominator for this ABR ratio.
SecondaryIntra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE)

This is an intra-participant comparison of the annualized bleeding rate (ABR) for treated bleeds on study versus pre-study in the NIS population previously treated with episodic FVIII in NIS BH29768. The number of treated bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.

Time frame:
Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for A+Bnise-FVIII Episodic: 25.71 [15.4-40.9] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for A+Bnise-Emicizumab: 34.71 [24.1-50.6] weeks)
Reported as:
Number · treated bleed rate per year
Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE)
treated bleed rate per yearA+Bnise: Pre-Study Episodic FVIII in NIS BH29768A+Bnise: Emicizumab Prophylaxis (Pre-study Episodic FVIII)
Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE)34.4 (27.45 to 43.14)1.0 (0.43 to 2.54)
Statistical analysis
  • A+Bnise: Pre-Study Episodic FVIII in NIS BH29768 vs A+Bnise: Emicizumab Prophylaxis (Pre-study Episodic FVIII) · Non-stratified Wald test · p = <0.0001 (Not controlled for type I error) · Abr ratio: 0.03 · 95% CI 0.014 to 0.067Arm A+Bnise: Emicizumab Prophylaxis is the numerator and Arm A+Bnise: Pre-Study Episodic FVIII is the denominator for this ABR Ratio.
SecondaryIntra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE)

This is an intra-participant comparison of the annualized bleeding rate (ABR) for all bleeds on study versus pre-study in the NIS population previously treated with episodic FVIII in NIS BH29768. The number of all bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the participant's number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.

Time frame:
Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for A+Bnise-FVIII Episodic: 25.71 [15.4-40.9] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for A+Bnise-Emicizumab: 34.71 [24.1-50.6] weeks)
Reported as:
Number · all bleed rate per year
Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE)
all bleed rate per yearA+Bnise: Pre-Study Episodic FVIII in NIS BH29768A+Bnise: Emicizumab Prophylaxis (Pre-study Episodic FVIII)
Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE)39.6 (31.94 to 49.04)1.6 (0.85 to 2.92)
Statistical analysis
  • A+Bnise: Pre-Study Episodic FVIII in NIS BH29768 vs A+Bnise: Emicizumab Prophylaxis (Pre-study Episodic FVIII) · Non-stratified Wald test · p = <0.0001 (Not controlled for type I error) · Abr ratio: 0.04 · 95% CI 0.023 to 0.068Arm A+Bnise: Emicizumab Prophylaxis is the numerator and Arm A+Bnise: Pre-Study Episodic FVIII is the denominator for this ABR Ratio.
SecondaryHemophilia A Quality of Life (Haem-A-QoL) Questionnaire Physical Health Subscore for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 25

The Haem-A-QoL questionnaire has been developed and used in hemophilia A participants, assessing very specific aspects of dealing with hemophilia. The questionnaire consists of items pertaining to 10 domains: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain ranges from 0 to 100 with lower scores reflective of better quality of life. Physical Health domain score is reported (range 0 to 100, with lower scores reflective of better physical health). The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.

Time frame:
Baseline, Week 25
Reported as:
Mean · units on a scale
Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Physical Health Subscore for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 25
units on a scaleArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2W
Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Physical Health Subscore for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 2544.32 ± 17.1531.81 ± 27.8628.35 ± 25.57
Statistical analysis
  • Arm C (Control): No Prophylaxis vs Arm A: Emicizumab 1.5 mg/kg QW · ANCOVA · p = 0.0891 (Statistical significance is controlled at the 2-sided, 0.05 alpha level.) · Mean difference (final values): 12.51 · 95% CI -1.96 to 26.98The difference in adjusted means was analyzed as Arm C minus Arm A.
  • Arm C (Control): No Prophylaxis vs Arm B: Emicizumab 3 mg/kg Q2W · ANCOVA · p = 0.0349 (Not controlled for type I error) · Mean difference (final values): 15.97 · 95% CI 1.16 to 30.78The difference in adjusted means was analyzed as Arm C minus Arm B.
SecondaryHaem-A-QoL Questionnaire Total Score for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 25

The Haem-A-QoL questionnaire has been developed and used in hemophilia A participants, assessing very specific aspects of dealing with hemophilia. The questionnaire consists of items pertaining to 10 domains: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain ranges from 0 to 100 with lower scores reflective of better quality of life. Haem-A-QoL Total Score is the average of all domain scores and it ranges from 0 to 100, with lower scores reflective of better quality of life. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.

Time frame:
Baseline, Week 25
Reported as:
Mean · units on a scale
Haem-A-QoL Questionnaire Total Score for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 25
units on a scaleArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2W
Haem-A-QoL Questionnaire Total Score for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 2529.95 ± 13.5624.04 ± 15.2621.39 ± 12.64
Statistical analysis
  • Arm C (Control): No Prophylaxis vs Arm A: Emicizumab 1.5 mg/kg QW · ANCOVA · p = 0.1269 (Not controlled for type I error) · Mean difference (final values): 5.91 · 95% CI -1.72 to 13.55The difference in adjusted means was analyzed as Arm C minus Arm A.
  • Arm C (Control): No Prophylaxis vs Arm B: Emicizumab 3 mg/kg Q2W · ANCOVA · p = 0.0317 (Not controlled for type I error) · Mean difference (final values): 8.56 · 95% CI 0.77 to 16.35The difference in adjusted means was analyzed as Arm C minus Arm B.
SecondaryEuropean Quality of Life 5-Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score in the Randomized Population at Week 25

EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L VAS. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.

Time frame:
Baseline, Week 25
Reported as:
Mean · units on a scale
European Quality of Life 5-Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score in the Randomized Population at Week 25
units on a scaleArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2W
European Quality of Life 5-Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score in the Randomized Population at Week 2572.57 ± 8.2076.61 ± 20.9981.72 ± 15.55
Statistical analysis
  • Arm C (Control): No Prophylaxis vs Arm A: Emicizumab 1.5 mg/kg QW · ANCOVA · p = 0.3402 (Not controlled for type I error) · Mean difference (final values): -4.04 · 95% CI -12.43 to 4.35The difference in adjusted means was analyzed as Arm C minus Arm A.
  • Arm C (Control): No Prophylaxis vs Arm B: Emicizumab 3 mg/kg Q2W · ANCOVA · p = 0.0373 (Not controlled for type I error) · Mean difference (final values): -9.15 · 95% CI -17.74 to -0.55The difference in adjusted means was analyzed as Arm C minus Arm B.
SecondaryEQ-5D-5L Questionnaire Index Utility Score in the Randomized Population at Week 25

EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L VAS. The EQ-5D-5L health state profile is designed to record the participant's current health state in 5 domains: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. Responses from the five domains are used to calculate a single index utility score on a scale of 0 to 1, with higher scores reflective of better quality of life. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.

Time frame:
Baseline, Week 25
Reported as:
Mean · units on a scale
EQ-5D-5L Questionnaire Index Utility Score in the Randomized Population at Week 25
units on a scaleArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2W
EQ-5D-5L Questionnaire Index Utility Score in the Randomized Population at Week 250.63 ± 0.200.76 ± 0.240.76 ± 0.18
Statistical analysis
  • Arm C (Control): No Prophylaxis vs Arm A: Emicizumab 1.5 mg/kg QW · ANCOVA · p = 0.0060 (Not controlled for type I error) · Mean difference (final values): -0.13 · 95% CI -0.22 to -0.04The difference in adjusted means was analyzed as Arm C minus Arm A.
  • Arm C (Control): No Prophylaxis vs Arm B: Emicizumab 3 mg/kg Q2W · ANCOVA · p = 0.0059 (Not controlled for type I error) · Mean difference (final values): -0.13 · 95% CI -0.23 to -0.04The difference in adjusted means was analyzed as Arm C minus Arm B.
SecondaryHemophilia-Specific Quality of Life - Short Form (Haemo-QoL-SF) Questionnaire Score in Adolescent Participants (12 to 17 Years of Age) in the Randomized Population at Week 25

The Haemo-QoL-SF contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia and treatment). Items are rated with five respective response options: never, seldom, sometimes, often, and always. Haemo-QoL-SF total score range from 0 to 100, where lower scores reflect better health-related quality of life.

Time frame:
Week 25

No measurements were reported for this outcome.

SecondaryPercentage of Participants With at Least One Adverse Event During the First 24 Weeks of the Study, Primary Analysis

The percentage of participants experiencing at least one adverse event, including all non-serious and serious adverse events, is reported here. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

Time frame:
From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event During the First 24 Weeks of the Study, Primary Analysis
percentage of participantsArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Percentage of Participants With at Least One Adverse Event During the First 24 Weeks of the Study, Primary Analysis33.394.485.750.087.3
SecondaryPercentage of Participants With at Least One Grade ≥3 Adverse Event During the First 24 Weeks of the Study, Primary Analysis

The World Health Organization (WHO) toxicity grading scale will be used for assessing adverse event severity. For adverse events that are not specifically listed in the WHO toxicity grading scale, a grade 3 adverse event is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a grade 4 adverse event is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

Time frame:
From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Grade ≥3 Adverse Event During the First 24 Weeks of the Study, Primary Analysis
percentage of participantsArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Percentage of Participants With at Least One Grade ≥3 Adverse Event During the First 24 Weeks of the Study, Primary Analysis5.68.311.409.3
SecondaryPercentage of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment During the First 24 Weeks of the Study, Primary Analysis

At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

Time frame:
From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment During the First 24 Weeks of the Study, Primary Analysis
percentage of participantsArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Percentage of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment During the First 24 Weeks of the Study, Primary Analysis002.900
SecondaryPercentage of Participants With at Least One Adverse Event of Changes From Baseline in Vital Signs During the First 24 Weeks of the Study, Primary Analysis

The percentage of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

Time frame:
From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event of Changes From Baseline in Vital Signs During the First 24 Weeks of the Study, Primary Analysis
percentage of participantsArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Percentage of Participants With at Least One Adverse Event of Changes From Baseline in Vital Signs During the First 24 Weeks of the Study, Primary Analysis00000
SecondaryPercentage of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings During the First 24 Weeks of the Study, Primary Analysis

Post-baseline physical examination abnormalities that were not present at baseline or worsened were reported as adverse events. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

Time frame:
From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings During the First 24 Weeks of the Study, Primary Analysis
percentage of participantsArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Percentage of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings During the First 24 Weeks of the Study, Primary Analysis00000
SecondaryPercentage of Participants With at Least One Adverse Event of Abnormal Laboratory Values During the First 24 Weeks of the Study, Primary Analysis

The percentage of participants with adverse events of abnormal laboratory values is reported here. An abnormal laboratory value is defined as a laboratory test result outside of the normal range for hematology or serum chemistries. It is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

Time frame:
From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event of Abnormal Laboratory Values During the First 24 Weeks of the Study, Primary Analysis
percentage of participantsArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Percentage of Participants With at Least One Adverse Event of Abnormal Laboratory Values During the First 24 Weeks of the Study, Primary Analysis05.617.16.34.8
SecondaryPercentage of Participants With at Least One Local Injection-Site Reaction During the First 24 Weeks of the Study, Primary Analysis

Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an "injection-site reaction" on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a "local injection-site reaction." At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

Time frame:
From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Local Injection-Site Reaction During the First 24 Weeks of the Study, Primary Analysis
percentage of participantsArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Percentage of Participants With at Least One Local Injection-Site Reaction During the First 24 Weeks of the Study, Primary Analysis025.020.012.533.3
SecondaryPercentage of Participants With at Least One Thromboembolic Event During the First 24 Weeks of the Study, Primary Analysis

At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.

Time frame:
From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Thromboembolic Event During the First 24 Weeks of the Study, Primary Analysis
percentage of participantsArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Percentage of Participants With at Least One Thromboembolic Event During the First 24 Weeks of the Study, Primary Analysis00000
SecondaryPercentage of Participants With at Least One Thrombotic Microangiopathy During the First 24 Weeks of the Study, Primary Analysis

At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

Time frame:
From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Thrombotic Microangiopathy During the First 24 Weeks of the Study, Primary Analysis
percentage of participantsArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Percentage of Participants With at Least One Thrombotic Microangiopathy During the First 24 Weeks of the Study, Primary Analysis00000
SecondaryPercentage of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction During the First 24 Weeks of the Study, Primary Analysis

At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.

Time frame:
From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction During the First 24 Weeks of the Study, Primary Analysis
percentage of participantsArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
Percentage of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction During the First 24 Weeks of the Study, Primary Analysis00000
SecondarySafety Summary of the Percentage of Emicizumab-Treated Participants With at Least One Adverse Event During the Study

Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. For participants whose emicizumab dose was up-titrated and those who opted for a change in dosing regimen (after implementation of protocol v4), only AEs that occurred before either one of those events are included. Hypersens.= hypersensitivity; Mod. = modification

Time frame:
From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)
Reported as:
Number · percentage of participants
Safety Summary of the Percentage of Emicizumab-Treated Participants With at Least One Adverse Event During the Study
percentage of participantsArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)All Emicizumab Participants
Any Adverse Event (AE)100.097.188.2100.098.0
AE with Fatal Outcome0.00.00.00.00.0
Serious AE27.822.95.925.423.2
AE Leading to Withdrawal from Treatment0.02.90.00.00.7
AE Leading to Dose Mod./Interruption2.80.00.01.61.3
Grade ≥3 AE36.128.65.920.624.5
Related AE30.634.323.547.637.7
Local Injection Site Reaction27.822.923.539.731.1
Systemic Hypersens./Anaphylac(tic/toid) Reaction0.00.00.00.00.0
Thromboembolic Event (TE)0.02.90.01.61.3
Thrombotic Microangiopathy (TMA)0.00.00.00.00.0
SecondaryLong-Term Efficacy of Emicizumab: Model-Based Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants

The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

Time frame:
From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)
Reported as:
Number · bleeds per year
Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants
bleeds per yearArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)All Emicizumab Participants
Treated Bleeds0.8 (0.48 to 1.29)0.7 (0.40 to 1.08)1.2 (0.47 to 3.19)1.5 (1.02 to 2.34)1.2 (0.92 to 1.56)
All Bleeds1.1 (0.72 to 1.66)1.1 (0.73 to 1.73)2.2 (1.16 to 4.15)2.4 (1.68 to 3.43)1.8 (1.46 to 2.29)
Treated Spontaneous Bleeds0.5 (0.23 to 1.03)0.2 (0.10 to 0.45)0.4 (0.12 to 1.35)0.5 (0.30 to 0.78)0.4 (0.29 to 0.58)
Treated Joint Bleeds0.4 (0.24 to 0.73)0.4 (0.21 to 0.68)0.7 (0.25 to 1.66)1.0 (0.60 to 1.76)0.7 (0.53 to 1.00)
Treated Target Joint Bleeds0.2 (0.11 to 0.43)0.2 (0.08 to 0.39)0.4 (0.13 to 1.31)0.6 (0.26 to 1.42)0.4 (0.29 to 0.66)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants

The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

Time frame:
From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)
Reported as:
Mean · bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants
bleeds per yearArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)All Emicizumab Participants
Treated Bleeds1.2 (0.04 to 5.83)0.8 (0.01 to 5.23)1.2 (0.05 to 5.95)1.7 (0.15 to 6.69)1.3 (0.07 to 6.07)
All Bleeds1.4 (0.09 to 6.29)1.3 (0.07 to 6.10)2.2 (0.32 to 7.58)2.6 (0.45 to 8.15)2.0 (0.23 to 7.19)
Treated Spontaneous Bleeds0.7 (0.00 to 4.97)0.3 (0.00 to 4.22)0.4 (0.00 to 4.48)0.6 (0.00 to 4.81)0.5 (0.00 to 4.68)
Treated Joint Bleeds0.6 (0.00 to 4.94)0.5 (0.00 to 4.64)0.6 (0.00 to 4.95)1.1 (0.04 to 5.78)0.8 (0.01 to 5.23)
Treated Target Joint Bleeds0.4 (0.00 to 4.54)0.3 (0.00 to 4.28)0.4 (0.00 to 4.50)0.6 (0.00 to 4.92)0.5 (0.00 to 4.64)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants

The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.

Time frame:
From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)
Reported as:
Median · bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants
bleeds per yearArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)All Emicizumab Participants
Treated Bleeds0.4 (0.00 to 1.28)0.4 (0.00 to 1.06)0.0 (0.00 to 2.48)0.5 (0.00 to 1.07)0.4 (0.00 to 1.15)
All Bleeds0.5 (0.09 to 1.77)0.8 (0.23 to 1.92)1.6 (0.20 to 3.8)1.0 (0.38 to 2.70)1.0 (0.19 to 2.37)
Treated Spontaneous Bleeds0.0 (0.00 to 0.51)0.0 (0.00 to 0.23)0.0 (0.00 to 0.65)0.0 (0.00 to 0.48)0.0 (0.00 to 0.40)
Treated Joint Bleeds0.2 (0.00 to 0.89)0.2 (0.00 to 0.49)0.0 (0.00 to 1.09)0.0 (0.00 to 0.59)0.2 (0.00 to 0.72)
Treated Target Joint Bleeds0.1 (0.00 to 0.55)0.0 (0.00 to 0.37)0.0 (0.00 to 0.81)0.0 (0.00 to 0.00)0.0 (0.00 to 0.38)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Reported as:
Mean · Treated bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
Treated bleeds per yearAll Emicizumab Participants
1 to 12 Weeks1.9 (0.21 to 7.04)
13 to 24 Weeks1.9 (0.20 to 6.99)
25 to 36 Weeks1.0 (0.02 to 5.57)
37 to 48 Weeks0.9 (0.01 to 5.35)
49 to 60 Weeks1.0 (0.02 to 5.54)
61 to 72 Weeks1.1 (0.04 to 5.72)
73 to 84 Weeks0.7 (0.01 to 5.12)
85 to 96 Weeks1.1 (0.03 to 5.68)
97 to 108 Weeks0.9 (0.01 to 5.32)
109 to 120 Weeks0.6 (0.00 to 4.83)
121 to 132 Weeks0.5 (0.00 to 4.72)
133 to 144 Weeks1.1 (0.03 to 5.68)
145 to 156 Weeks1.1 (0.03 to 5.70)
157 to 168 Weeks1.1 (0.04 to 5.78)
169 to 180 Weeks1.3 (0.06 to 6.05)
181 to 192 Weeks1.0 (0.02 to 5.56)
193 to 204 Weeks1.6 (0.13 to 6.57)
205 to 216 Weeks0.8 (0.01 to 5.15)
217 to 228 Weeks0.5 (0.00 to 4.59)
229 to 240 Weeks0.8 (0.01 to 5.30)
241 to 252 Weeks0.3 (0.00 to 4.21)
253 to 264 Weeks0.5 (0.00 to 4.72)
265 to 276 Weeks0.2 (0.00 to 4.09)
277 to 288 Weeks0.0 (NA to 3.69)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Reported as:
Median · Treated bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
Treated bleeds per yearAll Emicizumab Participants
1 to 12 Weeks0.0 (0.00 to 4.35)
13 to 24 Weeks0.0 (0.00 to 2.17)
25 to 36 Weeks0.0 (0.00 to 0.00)
37 to 48 Weeks0.0 (0.00 to 0.00)
49 to 60 Weeks0.0 (0.00 to 0.00)
61 to 72 Weeks0.0 (0.00 to 0.00)
73 to 84 Weeks0.0 (0.00 to 0.00)
85 to 96 Weeks0.0 (0.00 to 0.00)
97 to 108 Weeks0.0 (0.00 to 0.00)
109 to 120 Weeks0.0 (0.00 to 0.00)
121 to 132 Weeks0.0 (0.00 to 0.00)
133 to 144 Weeks0.0 (0.00 to 0.00)
145 to 156 Weeks0.0 (0.00 to 0.00)
157 to 168 Weeks0.0 (0.00 to 0.00)
169 to 180 Weeks0.0 (0.00 to 0.00)
181 to 192 Weeks0.0 (0.00 to 0.00)
193 to 204 Weeks0.0 (0.00 to 0.00)
205 to 216 Weeks0.0 (0.00 to 0.00)
217 to 228 Weeks0.0 (0.00 to 0.00)
229 to 240 Weeks0.0 (0.00 to 0.00)
241 to 252 Weeks0.0 (0.00 to 0.00)
253 to 264 Weeks0.0 (0.00 to 0.00)
265 to 276 Weeks0.0 (0.00 to 0.00)
277 to 288 Weeks0.0 (0.00 to 0.00)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Reported as:
Mean · All bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
All bleeds per yearAll Emicizumab Participants
1 to 12 Weeks3.8 (0.97 to 9.91)
13 to 24 Weeks2.8 (0.53 to 8.45)
25 to 36 Weeks1.8 (0.17 to 6.83)
37 to 48 Weeks1.4 (0.10 to 6.33)
49 to 60 Weeks1.5 (0.10 to 6.37)
61 to 72 Weeks1.6 (0.14 to 6.66)
73 to 84 Weeks1.2 (0.05 to 5.88)
85 to 96 Weeks1.4 (0.09 to 6.30)
97 to 108 Weeks1.3 (0.06 to 6.02)
109 to 120 Weeks0.8 (0.01 to 5.21)
121 to 132 Weeks0.8 (0.01 to 5.20)
133 to 144 Weeks1.2 (0.04 to 5.84)
145 to 156 Weeks1.3 (0.06 to 6.02)
157 to 168 Weeks1.4 (0.09 to 6.28)
169 to 180 Weeks1.7 (0.15 to 6.72)
181 to 192 Weeks1.4 (0.08 to 6.19)
193 to 204 Weeks1.7 (0.16 to 6.74)
205 to 216 Weeks1.1 (0.04 to 5.72)
217 to 228 Weeks0.6 (0.00 to 4.91)
229 to 240 Weeks0.9 (0.02 to 5.41)
241 to 252 Weeks0.4 (0.00 to 4.47)
253 to 264 Weeks0.6 (0.00 to 4.86)
265 to 276 Weeks0.2 (0.00 to 4.09)
277 to 288 Weeks0.0 (NA to 3.69)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Reported as:
Median · All bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
All bleeds per yearAll Emicizumab Participants
1 to 12 Weeks0.0 (0.00 to 4.35)
13 to 24 Weeks0.0 (0.00 to 4.35)
25 to 36 Weeks0.0 (0.00 to 4.35)
37 to 48 Weeks0.0 (0.00 to 0.00)
49 to 60 Weeks0.0 (0.00 to 0.00)
61 to 72 Weeks0.0 (0.00 to 0.00)
73 to 84 Weeks0.0 (0.00 to 0.00)
85 to 96 Weeks0.0 (0.00 to 0.00)
97 to 108 Weeks0.0 (0.00 to 0.00)
109 to 120 Weeks0.0 (0.00 to 0.00)
121 to 132 Weeks0.0 (0.00 to 0.00)
133 to 144 Weeks0.0 (0.00 to 0.00)
145 to 156 Weeks0.0 (0.00 to 0.00)
157 to 168 Weeks0.0 (0.00 to 0.00)
169 to 180 Weeks0.0 (0.00 to 0.00)
181 to 192 Weeks0.0 (0.00 to 0.00)
193 to 204 Weeks0.0 (0.00 to 0.00)
205 to 216 Weeks0.0 (0.00 to 0.00)
217 to 228 Weeks0.0 (0.00 to 0.00)
229 to 240 Weeks0.0 (0.00 to 0.00)
241 to 252 Weeks0.0 (0.00 to 0.00)
253 to 264 Weeks0.0 (0.00 to 0.00)
265 to 276 Weeks0.0 (0.00 to 0.00)
277 to 288 Weeks0.0 (0.00 to 0.00)
SecondaryLong-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Reported as:
Mean · Treated spontaneous bleeds per year
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
Treated spontaneous bleeds per yearAll Emicizumab Participants
1 to 12 Weeks0.7 (0.00 to 4.98)
13 to 24 Weeks0.7 (0.00 to 5.00)
25 to 36 Weeks0.3 (0.00 to 4.30)
37 to 48 Weeks0.4 (0.00 to 4.53)
49 to 60 Weeks0.5 (0.00 to 4.60)
61 to 72 Weeks0.3 (0.00 to 4.25)
73 to 84 Weeks0.1 (0.00 to 3.95)
85 to 96 Weeks0.4 (0.00 to 4.48)
97 to 108 Weeks0.2 (0.00 to 4.14)
109 to 120 Weeks0.2 (0.00 to 4.03)
121 to 132 Weeks0.1 (0.00 to 3.96)
133 to 144 Weeks0.6 (0.00 to 4.78)
145 to 156 Weeks0.6 (0.00 to 4.87)
157 to 168 Weeks0.2 (0.00 to 4.09)
169 to 180 Weeks0.4 (0.00 to 4.50)
181 to 192 Weeks0.2 (0.00 to 4.01)
193 to 204 Weeks0.1 (0.00 to 3.80)
205 to 216 Weeks0.3 (0.00 to 4.24)
217 to 228 Weeks0.1 (0.00 to 3.81)
229 to 240 Weeks0.1 (0.00 to 3.94)
241 to 252 Weeks0.1 (0.00 to 3.82)
253 to 264 Weeks0.3 (0.00 to 4.29)
265 to 276 Weeks0.2 (0.00 to 4.09)
277 to 288 Weeks0.0 (NA to 3.69)
SecondaryLong-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants

The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.

Time frame:
1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Reported as:
Median · Treated spontaneous bleeds per year
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
Treated spontaneous bleeds per yearAll Emicizumab Participants
1 to 12 Weeks0.0 (0.00 to 0.00)
13 to 24 Weeks0.0 (0.00 to 0.00)
25 to 36 Weeks0.0 (0.00 to 0.00)
37 to 48 Weeks0.0 (0.00 to 0.00)
49 to 60 Weeks0.0 (0.00 to 0.00)
61 to 72 Weeks0.0 (0.00 to 0.00)
73 to 84 Weeks0.0 (0.00 to 0.00)
85 to 96 Weeks0.0 (0.00 to 0.00)
97 to 108 Weeks0.0 (0.00 to 0.00)
109 to 120 Weeks0.0 (0.00 to 0.00)
121 to 132 Weeks0.0 (0.00 to 0.00)
133 to 144 Weeks0.0 (0.00 to 0.00)
145 to 156 Weeks0.0 (0.00 to 0.00)
157 to 168 Weeks0.0 (0.00 to 0.00)
169 to 180 Weeks0.0 (0.00 to 0.00)
181 to 192 Weeks0.0 (0.00 to 0.00)
193 to 204 Weeks0.0 (0.00 to 0.00)
205 to 216 Weeks0.0 (0.00 to 0.00)
217 to 228 Weeks0.0 (0.00 to 0.00)
229 to 240 Weeks0.0 (0.00 to 0.00)
241 to 252 Weeks0.0 (0.00 to 0.00)
253 to 264 Weeks0.0 (0.00 to 0.00)
265 to 276 Weeks0.0 (0.00 to 0.00)
277 to 288 Weeks0.0 (0.00 to 0.00)
SecondaryPercentage of Participants With Anti-Emicizumab Antibodies at Any Time Post-Baseline During the Study

A validated enzyme-linked immunosorbent assay (ELISA) method was used to analyze the levels of anti-drug antibodies (ADAs) against emicizumab in plasma. A sample was considered positive for anti-emicizumab antibodies if the test result reached or exceeded a pre-determined threshold. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample.

Time frame:
From Baseline to discontinuation from study (median [min-max] observation period for all emicizumab participants: 262.3 [14.4-288.3] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Emicizumab Antibodies at Any Time Post-Baseline During the Study
percentage of participantsArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)All Emicizumab Participants
Total ADA Positive (Boosted+Induced)8.35.70.01.64.0
ADA Positive (Treatment Boosted)0.02.90.00.00.7
ADA Positive (Treatment Induced)8.32.90.01.63.3
SecondaryPercentage of Participants With De Novo Development of Factor VIII (FVIII) Inhibitors

Levels of anti-FVIII antibodies (inhibitors) were analyzed using a validated FVIII activity assay. A participant was considered to have developed de novo FVIII inhibitors if the inhibitor levels detected in a post-baseline sample reached or exceeded a pre-determined threshold.

Time frame:
From Baseline to discontinuation from study (median [min-max] observation period for all emicizumab participants: 262.3 [14.4-288.3] weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With De Novo Development of Factor VIII (FVIII) Inhibitors
percentage of participantsArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)All Emicizumab Participants
Percentage of Participants With De Novo Development of Factor VIII (FVIII) Inhibitors0.00.00.00.00.0
SecondaryTrough Plasma Concentration (Ctrough) of Emicizumab

Trough plasma concentrations of emicizumab were analyzed using a validated Enzyme Linked Immunosorbent Assay (ELISA). The lower limit of quantification (LLOQ) was 100 nanograms per milliliter (ng/mL). Because participants in Arm C (Control) switched from no prophylaxis to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm C (Emi) are expressed relative to first emicizumab dose.

Time frame:
Predose at Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181, 193, 205, 217, 229, 241, 253, 265, and 277
Reported as:
Mean · micrograms per milliliter (μg/mL)
Trough Plasma Concentration (Ctrough) of Emicizumab
micrograms per milliliter (μg/mL)Arm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)Arms A and D: Emicizumab 1.5 mg/kg QWArms B and C (Emi): Emicizumab 3 mg/kg Q2W
Week 1NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Week 216.3 ± 6.116.8 ± 5.919.6 ± 8.217.3 ± 5.416.9 ± 5.717.7 ± 6.8
Week 329.1 ± 9.329.2 ± 6.533.0 ± 12.630.5 ± 8.730.0 ± 8.930.5 ± 9.0
Week 441.9 ± 11.841.4 ± 9.747.9 ± 15.042.4 ± 9.442.2 ± 10.343.6 ± 11.9
Week 548.0 ± 13.748.8 ± 12.359.6 ± 20.754.5 ± 12.552.2 ± 13.252.4 ± 16.2
Week 747.9 ± 16.148.4 ± 11.455.2 ± 16.252.4 ± 13.350.9 ± 14.450.7 ± 13.5
Week 949.0 ± 16.446.4 ± 14.153.1 ± 15.755.1 ± 16.153.0 ± 16.448.7 ± 14.9
Week 1348.7 ± 18.347.6 ± 16.047.9 ± 18.155.0 ± 15.952.8 ± 16.947.7 ± 16.5
Week 1754.3 ± 24.048.9 ± 17.743.4 ± 16.255.0 ± 16.554.7 ± 19.347.0 ± 17.2
Week 2150.7 ± 20.247.3 ± 15.545.6 ± 18.855.1 ± 16.253.6 ± 17.746.7 ± 16.4
Week 2550.5 ± 21.747.6 ± 18.951.8 ± 23.454.8 ± 16.853.3 ± 18.749.0 ± 20.4
Week 3356.3 ± 25.352.9 ± 22.452.0 ± 21.359.1 ± 18.558.1 ± 20.952.6 ± 21.9
Week 4154.8 ± 24.248.4 ± 18.850.7 ± 24.459.6 ± 21.457.9 ± 22.449.2 ± 20.6
Week 4955.4 ± 22.952.2 ± 20.254.3 ± 21.360.2 ± 19.958.5 ± 21.052.9 ± 20.4
Week 6155.3 ± 21.452.0 ± 21.152.5 ± 19.861.1 ± 22.559.1 ± 22.152.2 ± 20.5
Week 7354.4 ± 21.551.6 ± 21.347.8 ± 18.458.5 ± 19.257.1 ± 20.050.4 ± 20.3
Week 8548.8 ± 17.446.4 ± 20.447.7 ± 17.956.7 ± 18.553.8 ± 18.546.8 ± 19.5
Week 9752.6 ± 20.050.9 ± 21.051.7 ± 28.358.5 ± 18.756.3 ± 19.351.1 ± 22.9
Week 10953.9 ± 19.252.3 ± 19.546.4 ± 27.059.0 ± 19.157.0 ± 19.150.5 ± 21.7
Week 12158.8 ± 21.155.0 ± 22.050.0 ± 25.257.1 ± 18.257.7 ± 19.253.5 ± 22.7
Week 13355.3 ± 26.054.7 ± 18.554.6 ± 26.959.3 ± 19.257.7 ± 22.154.7 ± 20.9
Week 14554.1 ± 23.751.3 ± 17.744.8 ± 11.655.7 ± 20.455.0 ± 21.649.9 ± 16.6
Week 15757.6 ± 27.852.2 ± 21.446.8 ± 24.055.9 ± 23.756.6 ± 25.150.6 ± 21.9
Week 16953.9 ± 21.850.3 ± 19.645.8 ± 20.656.4 ± 18.055.3 ± 19.448.8 ± 19.6
Week 18159.8 ± 24.848.8 ± 22.143.5 ± 26.257.5 ± 21.358.6 ± 22.746.5 ± 23.4
Week 19353.9 ± 21.052.4 ± 24.642.1 ± 19.160.5 ± 19.657.5 ± 20.249.5 ± 23.3
Week 20553.5 ± 20.851.9 ± 22.454.2 ± 31.158.6 ± 24.156.4 ± 22.652.6 ± 24.6
Week 21754.4 ± 20.855.0 ± 20.650.8 ± 26.160.8 ± 23.258.3 ± 22.253.6 ± 22.1
Week 22954.9 ± 20.947.9 ± 18.953.5 ± 30.454.4 ± 19.354.6 ± 19.749.8 ± 23.1
Week 24151.9 ± 19.350.2 ± 16.852.0 ± 36.160.1 ± 23.356.8 ± 21.950.6 ± 22.2
Week 25358.6 ± 28.746.5 ± 17.840.3 ± 43.958.4 ± 24.758.5 ± 26.045.2 ± 23.9
Week 26558.7 ± 25.847.3 ± 14.5—60.0 ± 23.959.5 ± 24.247.3 ± 14.5
Week 27771.9 ± 34.249.0 ± 16.2—61.3 ± 17.269.2 ± 30.149.0 ± 16.2

Adverse events

Collected over Total observation time for all participants: From enrollment until study completion (median [min-max] 262.3 [14.4-288.3] weeks); Arm C (Control): From enrollment to 24 weeks on no prophylaxis (median [min-max]: 24.00 [14.4-25.0] weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm C (Control): No Prophylaxis0/18 (0%)1/18 (5.6%)5/18 (27.8%)
Arm A: Emicizumab 1.5 mg/kg QW0/36 (0%)10/36 (27.8%)35/36 (97.2%)
Arm B: Emicizumab 3 mg/kg Q2W0/35 (0%)8/35 (22.9%)33/35 (94.3%)
Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis)0/17 (0%)1/17 (5.9%)15/17 (88.2%)
Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)0/63 (0%)16/63 (25.4%)61/63 (96.8%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
GINGIVAL ABSCESSInfections and infestations0/180/360/351/170/63
HAEMATOMAVascular disorders1/181/360/350/171/63
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/180/361/350/170/63
ARRHYTHMIACardiac disorders0/180/361/350/170/63
ATRIAL FLUTTERCardiac disorders0/180/361/350/170/63
HYPERPARATHYROIDISMEndocrine disorders0/180/361/350/170/63
MELAENAGastrointestinal disorders0/181/361/350/170/63
UPPER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders0/180/361/350/170/63
FEMUR FRACTUREInjury, poisoning and procedural complications0/180/361/350/170/63
TENDON RUPTUREInjury, poisoning and procedural complications0/180/361/350/170/63
Most frequent other events
Showing 10 of 101
Most frequent other events
EventArm C (Control): No ProphylaxisArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis)Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
ARTHRALGIAMusculoskeletal and connective tissue disorders1/1816/3611/353/1725/63
INJECTION SITE REACTIONGeneral disorders0/1810/368/354/1724/63
NASOPHARYNGITISInfections and infestations1/189/368/353/1720/63
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/188/366/353/1714/63
HEADACHENervous system disorders1/187/367/352/1714/63
INFLUENZAInfections and infestations0/187/364/352/179/63
ABDOMINAL PAINGastrointestinal disorders0/183/360/353/172/63
BACK PAINMusculoskeletal and connective tissue disorders1/186/363/352/178/63
LIGAMENT SPRAINInjury, poisoning and procedural complications0/182/361/351/1710/63
DIARRHOEAGastrointestinal disorders1/184/365/352/176/63

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm C (Control): No Prophylaxis, Then EmicizumabArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)Total
Mean37.8 ± 12.939.8 ± 14.040.4 ± 11.436.4 ± 14.438.3 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)Arm C (Control): No Prophylaxis, Then EmicizumabArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)Total
Female00000
Male18363563152
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm C (Control): No Prophylaxis, Then EmicizumabArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)Total
Hispanic or Latino045716
Not Hispanic or Latino17323053132
Unknown or Not Reported10034
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm C (Control): No Prophylaxis, Then EmicizumabArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)Total
American Indian or Alaska Native00000
Asian46101232
Native Hawaiian or Other Pacific Islander01001
Black or African American33118
White11242047102
More than one race00000
Unknown or Not Reported02439
Number of Participants with <9 or ≥9 Bleeds in the Last 24 Weeks Prior to Study Entry
Number of Participants with <9 or ≥9 Bleeds in the Last 24 Weeks Prior to Study Entry(Participants)Arm C (Control): No Prophylaxis, Then EmicizumabArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)Total
Less Than (<) 9 Bleeds4955371
Greater Than or Equal To (≥) 9 Bleeds1427301081
Number of Target Joints in the Last 24 Weeks Prior to Study Entry
Number of Target Joints in the Last 24 Weeks Prior to Study Entry(target joints)Arm C (Control): No Prophylaxis, Then EmicizumabArm A: Emicizumab 1.5 mg/kg QWArm B: Emicizumab 3 mg/kg Q2WArm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)Total
Mean2.2 ± 1.42.1 ± 1.42.2 ± 1.71.0 ± 1.61.7 ± 1.6
08

Study locations

39 sites
  • Santa Monica Oncology Center
    Santa Monica, California 90403, United States
  • Georgetown Uni Medical Center; Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • University of Florida
    Gainesville, Florida 32607, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Dana-Farber Cancer Institute; Brigham and Women's Cancer Center
    Boston, Massachusetts 02115, United States
  • Children's Hospital of Michigan; Pediatrics
    Detroit, Michigan 48201, United States
  • Cornell Univ Medical College; Hematology-Oncolog
    New York, New York 10021, United States
  • Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia
    Seattle, Washington 98104, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit
    Melbourne, Victoria 3004, Australia
  • The Perth Blood Institute
    Nedlands, Western Australia 6009, Australia
  • ICIC
    San Jose, 1000, Costa Rica
  • Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique
    Bron, 69677, France
  • CH de Bicetre; Centre de Traitement d' Hemophilie
    Le Kremlin Bicetre, 94275, France
  • Groupe Hospitalier Necker Enfants Malades
    Paris, 75015, France
  • Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin
    Bonn, 53127, Germany
  • St James's Hospital
    Dublin, 8, Ireland
  • IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"
    Milano, Lombardia 20122, Italy
  • AOU Careggi; SOD Malattie Emorragiche
    Firenze, Toscana 50134, Italy
  • Nagoya University Hospital
    Aichi, 466-8560, Japan
  • St. Marianna University Hospital
    Kanagawa, 216-8511, Japan
  • Sendai Medical Center
    Miyagi, 983-8520, Japan
  • Nara Medical University Hospital
    Nara, 634-8522, Japan
  • NHO Osaka National Hospital
    Osaka, 540-0006, Japan
  • Tokyo Medical University Hospital
    Tokyo, 160-0023, Japan
  • Ogikubo Hospital
    Tokyo, 167-0035, Japan
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii
    Gdansk, 80-952, Poland
  • SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
    Lublin, 20-081, Poland
  • ALVAMED Lekarskie Gabinety Specjalistyczne
    Poznań, 60-549, Poland
  • Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych
    Warsaw, 02-776, Poland
  • Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center
    Johannesburg, 2193, South Africa
  • Hospital Universitario la Paz; Servicio de Hematologia
    Madrid, 28046, Spain
  • Hospital Universitario Virgen del Rocio; Servicio de Hematologia
    Sevilla, 41013, Spain
  • Changhua Christian Hospital
    Chang Hua, 500, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • Taipei Medical University Hospital
    Taipei, 110, Taiwan
  • Cardiff and Vale NHS Trust
    Cardiff, CF14 4XW, United Kingdom
  • Royal Free Hospital; Haemophilia Centre
    London, NW3 2QG, United Kingdom
09

References and documents

Publications

  • Kruse-Jarres R, Peyvandi F, Oldenburg J, Chang T, Chebon S, Doral MY, Croteau SE, Lambert T, Kempton CL, Pipe SW, Ko RH, Trzaskoma B, Dhalluin C, Bienz NS, Niggli M, Lehle M, Paz-Priel I, Young G, Jimenez-Yuste V. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv. 2022 Dec 27;6(24):6140-6150. doi: 10.1182/bloodadvances.2022007458. PubMed 35939785 ↗
  • Kiialainen A, Niggli M, Kempton CL, Castaman G, Chang T, Paz-Priel I, Adamkewicz JI, Levy GG. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia. 2022 Nov;28(6):1033-1043. doi: 10.1111/hae.14642. Epub 2022 Jul 29. PubMed 35905294 ↗
  • Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jimenez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550. PubMed 30157389 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Sep 2017, 11 months.

Results were first posted in Nov 2018, 1 year 1 month after primary completion.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 11 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2016
First posted
Jul 28, 2016
StartActual
Sep 27, 2016
Primary completionActual
Sep 15, 2017
CompletionActual
May 12, 2022
Results first posted
Nov 14, 2018
Last update
Nov 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02847637
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 28, 2016
Start date
Sep 27, 2016
Primary completion
Sep 15, 2017
Completion
May 12, 2022
Results posted
Nov 14, 2018
Last update
Nov 16, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emicizumab

Start the discussion